Diagnostic assertiveness of cerebellar pilocytic astrocytoma in the pediatric age

Asertividad diagnóstica de los astrocitomas pilocíticos cerebelosos en la edad pediátrica.

Ana L. Pichardo-Ávalos [a]

Abstract:

Pilocytic astrocytoma of the cerebellum in the pediatric age is the most frequent benign tumor lesion of the nervous system in children according to the WHO. International literature mentions that being low-grade tumors they have a high curative capacity. If the entire tumor is resected, when it is completely removed, survival increases with a high quality of life for children who presented this pathology and was treated on time. However, the delay in diagnosis and therefore in its treatment could generate the possibility of tumor transformation, the malignant nature of the transformed injuries has a very high morbidity and mortality, without mentioning that the degree of cognitive sequelae greatly affects the quality of life of the survivors. That is why the training of pediatric and non-pediatric first contact doctors imply a great responsibility since it gives the population and patients suffering from this nosology the possibility to improve their future life, as well as reduce the cost of the impact caused by the injuries they suffer. On the other hand, these tumors can transform generating devastating prognoses, without taking into account the economic and social repercussions of patients suffering from a low-grade tumor. When it is detected and treated assertively in a timely manner, it offers them greater opportunities than those who did not have such a timely diagnosis.

Keywords:

Astrocytoma, pilocytic astrocytoma, low-grade brain tumors, quality of life, timely treatment.

Resumen:

Los astrocitomas pilocíticos del cerebelo en la edad pediátrica son la lesión tumoral benigna del sistema nervioso más frecuente en niños según la OMS, la literatura internacional menciona que al ser tumores de bajo grado tienen una alta capacidad curativa, si se reseca todo el tumor, cuando es removido en su totalidad, la supervivencia aumenta, con una alta calidad de vida para los niños que presentaron esta patología y fueron tratados oportunamente, sin embargo, el retraso en el diagnóstico y por ende en su tratamiento podría generar la posibilidad de transformación tumoral, la naturaleza maligna de las lesiones transformadas tienen una morbilidad y mortalidad muy altas, sin mencionar que el grado de secuelas cognitivas que perjudica en gran medida la calidad de vida de los supervivientes. Es por ello, que la formación de los médicos de primer contacto, pediatras y no pediatras conlleva una gran responsabilidad, pues otorga a la población y a los pacientes que padecen esta nosología, la posibilidad de mejora en una vida futura, así como, reduce el costo del impacto de las lesiones que sufren, por otra parte estos tumores pueden transformarse, generando pronósticos devastadores, sin tener en cuenta que la repercusión económica y social de los pacientes que padecen un tumor de bajo grado, cuando se detecta y trata asertivamente, en forma oportuna, les brinda mayores oportunidades que aquellos que no tuvieron tal puntualidad diagnóstica.

Palabras Clave:

Astrocitomas, astrocitomas pilocíticos, tumores cerebrales de bajo grado, calidad de vida, tratamiento oportuno.

INTRODUCTION

Central nervous system tumors are a heterogeneous group of multiple neoplasms that share considerable morbidity and mortality.[1] Central nervous system (CNS) tumors represent 2% of all neoplasms.[2] Being such that they represent a public health problem worldwide,[2] mainly for the age group between 0-14 years.[3] The Central Brain Tumor Registry of the United States (CBTRUS), in the 2020 CBTRUS Statistical Report, CBTRUS presents observed and relative survival, based on the Centers for Disease Control and Prevention (CDC) and the National Program of Cancer Registries (NPCR) data, this dataset provides population-based information for 93.6% of the US population for the years 2001 to 2016 and is a subset of the data used for the incidence calculations presented in the 2020 CBTRUS Statistical Report.[2] In pediatric age, the incidence of presentation is

[a] Corresponding author, Consultorio Particular, https://orcid.org/0000-0003-4118-5374, Email: alpa-med@hotmail.com

increasing and the essential concern is the morbidity[3] of each sequela that may present, thus reducing the quality of life of patients who suffer from a central nervous system tumor at an early age.[4] Brain tumors deserve a separate consideration from the rest of neoplasic lesions of pediatric age for several reasons, among which are, their anatomical distribution that strongly favors tumor behavior and neurodevelopment of the infant, as well as an immature neurocognitive state.[2,5] Brain tumors are the most common solid tumors in children,[6] and are the leading cause of childhood cancer-related deaths.[7] Low-grade gliomas comprise several subgroups, including pilocytic, pilomyxoid, subependymal giant cell, and diffuse astrocytomas.[6] Low-grade gliomas, specifically astrocytoma, are the most frequent presentation in tumors of the central nervous system,[2,3,7] which is why our main objective will be to denote the clinical information previous to the diagnosis established in the literature about these tumors.

DEFINITION

Pilocytic astrocytoma (PA) is a World Health Organization (WHO) grade 1 tumor,[3] that is the most common primary brain tumor in children aged between 5 and 14 years, and the second most common brain tumor in children aged from 0 to 4 and 15 to 19 years old.[6] It is most often located in the cerebellum, but it can occur in other brain regions.[5-7] In children, PA typically behaves indolent and may be surgically curable.[8] Radiation therapy is generally reserved for patients with recurrent or progressive tumors in whom additional surgery is not possible.[5-7] Signs and symptoms of raised intracranial pressure may simulate other disorders and often confuse the clinical presentation.[8] Two cancer predisposing syndromes, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex, are associated with an increased frequency of pilocytic astrocytomas and subependymal giant cell astrocytomas, respectively.[9] However, most low-grade gliomas (LGGs) arise sporadically.[9]

CLASSIFICATION

Pilocytic astrocytoma, previously known as cystic cerebellar astrocytoma or juvenile pilocytic astrocytoma,[10] was first described in 1931 by Harvey Cushing, based on a case series of cerebellar astrocytoma; though he never used these terms but rather described a spongioblastoma.[10,11] They are low-grade, and usually well circumscribed tumors, which tend to occur in young patients.[10,11] According to the WHO classification of central nervous system tumors, they are considered grade I gliomas and have a good prognosis.[11,12.] Astrocytic tumors arise from astrocytes and are the most common tumor of glial origin.[2,12] The WHO 2016 categorized these tumors as either "diffuse gliomas" or "other astrocytic tumors".[11-14] Diffuse gliomas include grade II and III diffuse astrocytoma, grade IV glioblastoma, and diffuse gliomas of childhood.[11] The "other astrocytic tumors" group include PA, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and anaplastic

pleomorphic xanthoastrocytoma.[11-14] The classification system described above is histological.[14] It is worth noting that the 2016 WHO classification gives more importance to genetic and molecular markers for categorizing gliomas; however, PA is essentially a histological diagnosis.[11] In the same way the update of the WHO classification system in its 2021 edition, PA is graded as a low-grade glioma or grade 1 to the circumscribed tumor, with a higher incidence in the posterior fossa and with histology compatible with pilocytic astrocytoma.[15]

EPIDEMIOLOGY

In children and adolescents (from 0 to 19 years old), the incidence rate of primary malignant and non-malignant brain and other CNS tumors was 6.14 per 100,000 between 2013 and 2017.[3] Incidence was higher in females compared to males (6.22 versus 6.07 per 100,000), in Caucasian compared to African Americans (6.36 versus 4.83 per 100,000), and non-Hispanics compared to Hispanics (6.42 versus 5.26 per 100,000).[3,16] Brain and other CNS tumors (both malignant and non-malignant) were the most common cancer site in persons aged 0-14 years,[2] with an average annual age-adjusted incidence rates (AAAIR of) 5.83 per 100,000 population.[3] Brain and other CNS tumors were the most common cancer in both males and females in this age group.[2,3] Incidence rates of pilocytic astrocytoma, germ cell tumors, and embryonal tumors were higher in the younger groups and lower within the older groups.[2,3] The distribution of reported tumors with histologically confirmed diagnosis from 2013 to 2017 is presented by histology and reported WHO grade in 65.2% of tumors had complete WHO grade information, but there was substantial variation by histology.[2,3,16] The histologic types with the highest WHO grade were anaplastic oligodendroglioma (93.7%), anaplastic astrocytoma (95.7%), and oligoastrocytic tumors (94.8%).[2-4,16] This for the WHO graduation in its 2016 edition.[2-4,15,17] Although the overall incidence of primary brain and other CNS tumors was slightly higher in African Americans compared to Caucasians, the incidence of many specific histologies was significantly higher among Caucasians.[15] Incidence rates for glioblastoma (p <0.0001), all other astrocytomas (p <0.0001), and nerve sheath tumors (p <0.0001) were approximately 2 times higher in Caucasians than in African Americans.[3,16] Average annual incidence rates were higher for tumors of neuroepithelial tissue (3.88 per 100,000 population).[2,3,15] Among these tumors, the most common histologies were pilocytic astrocytoma (0.92 per 100,000 population).[2,3] Median survival was not able to be estimated for pilocytic astrocytoma, ependymal tumors, or germ cell tumors as >50% of individuals remained alive during the 15 year follow up period.[2,3] CBTRUS incorporate treatment patterns which may explain differences between these population-level estimates and other published estimates.[2,3] Demographic factors such as age at diagnosis, sex, race and ethnicity are known to have a significant effect on survival time after diagnosis in primary brain and other CNS tumors.[2,3,15-17] In Mexico, Chico-Ponce de Leon, et al; In 2006 conducted a study in which he

reported that, for the Mexican population studied in the Hospital Infantil de México Federico Gómez (HIMFG), the most frequently found brain tumors of the central nervous system were astrocytomas, with 32%, and medulloblastomas, with 19%.[18] Craniopharyngiomas with 11% and ependymomas with 10.24%.[18] The authors did not find a significant difference in incidence by gender.[18] Most statistics report a higher frequency of tumors in the posterior fossa in children, with a frequency of between 60 and 70%.[10,18]

CLINICAL MANIFESTATIONS

The clinical data that causes a tumor lesion of the central nervous system are divided into two groups: focal symptoms and generalized symptoms.[1,2,15] Focal symptoms are related to the location of tumor and its extension[1,18] and generalized symptoms are those that are related to growth and compression generated secondarily, which leads to headache, nausea, papilledema and seizures, among others.[1,3,18] Therefore, it is suggested to approach the clinic from the two points previously mentioned,

a) Manifestations of intracranial hypertension: 1. Headache in 55 to 77% of cases[19-27] 2. Irritability is more frequent the younger the patient.[18,28] 3. "Projectile" vomiting, with a frequency of 39 to 60% in supratentorials, and 73 to 78% in infratentorials.[18-22,29,30] 4. Papilledema present in 37% of supratentorial cases, and in 68-90% of infratentorial cases. [18,25,26,29] 5. Diplopia observed in 8 to 65% of cases.[29,31] 6. Increased head circumference (it is of diagnostic value in children under two or three years of age),[18] and it occurs in 6% to 16% in infratentorial tumors.[18,32,33]

b) Location data (the location data will denote which of the intracranial sites are affected by the tumor lesion and it has been observed that radiotoxicity can develop similar problems in brain targeting)[1,3,18] 1. Cranial nerves,[18,25] 2. Areas of cerebral eloquence (according to Brodmann's areas),[5,18] 3. Brain stem and nuclei of autonomic eloquence (hypothalamic, respiratory, etc.).[1,3,18] 4. Motor and sensory regions.[18]

Similarly, there are two other groups of complementary signs and symptoms and they are: c) Signs of neuronal irritation (epilepsy),[1,18] and d) Behavioral disorders.[1,18]

Other authors conclude that the most common symptoms were headache, vomiting and nausea.[34] That is why epidemiology reports in order of appearance the astrocytomas, being 95% more frequent in the posterior fossa,[2,3,16,18] as first-contact doctors, the commitment is in detecting lesions of the cerebellar hemisphere,[1,18] which cause peripheral ataxia, dysmetria, intention tremor, nystagmus, and dysarthria.[34] Posterior fossa lesions can also cause cranial nerve palsy.[18,33,34] Diplopia can occur due to abducens palsy due to stretching of the nerve.[1,18,34] They may also have blurred vision due to papilledema.[34] Seizures are rare with posterior fossa lesions.[34] Cerebellar location represents 95% of PA in the pediatric age versus 26% of PA in adults.[2,3] At the time of diagnosis, most patients will have clinical signs of cerebellar dysfunction,[1,2,18] especially appendicular dysmetria and truncal unsteadiness,[13,18,34] the papilledema and extraocular movement abnormalities are

somewhat more variable.[35] Dysmetria and gait unsteadiness are inconsistent in early presentation and may be confused with photo-phobia or psychological manifestations.[35] Patients tend to develop hydrocephalus later in the course of illness, with associated symptoms of increased intracranial pressure.[18,34,35]

PHYSIOPATHOLOGY

The evolution of medical science in conjunction with molecular advances have given us the ability to demonstrate the alterations generated by many of the pathologies.[34-36] In recent years, giant steps have been taken in oncology in terms of molecular diagnosis, which leads us to understand why and how tumor lesions happen. In this case of pilocytic astrocytoma, a series of molecular analyzes showed that many pilocytic astrocytomas exhibit translocations or, less frequently, activating mutations of the BRAF gene, which can promote the development of tumors.[13,36,37] BRAF-KIAA fusions are common in pilocytic tumors of the cerebellum (pilocytic astrocytoma) and tumors of the optic pathway and cause constitutive activation of the BRAF protein,[36,37] while BRAF mutations are more common in gangliogliomas, pleomorphic xanthoastrocytomas, and astrocytomas cerebellar pilocytic, they infiltrated for what they are not originated in the posterior fossa.[38] Tumors lacking BRAF fusions or mutations often have alterations in other components of the mitogen-activated protein kinase (MAPK) signaling pathway, including NF1 mutations and RAF fusions. This convergence of mutations on a single downstream pathway prompted interest in the targeted inhibition of MAPK signaling as a therapy for these tumors.[36-38] Most PA are thought to be sporadic mutations rather than inherited.[36-38] BRAF gene alterations and MAPK signaling pathway alterations have been found in the majority of PA.[11,39,40] BRAF is an intracellular serine/threonine kinase involved in the activation of the mitogen-activated kinase (MAPK) pathway.[41] BRAF is a proto-oncogene, mutations of which have been found to cause human cancers.[41,42] Oncogene-induced senescence (OIS) is a key biological mechanism that controls tumor growth and behavior.[43,44] Further supporting the idea that these tumors may be subject to OIS.[44,45] Additionally, loss of CDKN2A the MAPK alteration in PA is associated with a worse clinical outcome, suggesting that this pathway is crucial for OIS in these tumors.[46] The most common genetic alteration found in PA is the tandem duplication at 7q34, which produces a fusion between two genes, KIAA1549 and BRAF.[46] This fusion results in loss of the BRAF autoregulatory domain at the amino-terminus and constitutive kinase activity of the Ras/ERK pathway.[46,47] The KIAA1549-BRAF fusion is found in 60–94% of PA, more commonly in those arising in the cerebellum.[35,47]

DIAGNOSIS

Diagnosis is the initial challenge of cerebellar pilocytic astrocytomas, since having a highly variable clinic this can be a watershed for multiple differential diagnoses. Timely diagnosis is of vital importance as it reduces the risk of malignant

transformation and reduction of sequelae.[1,3,18] We will divide the diagnosis into the following parts:

Clinical

PA may appear with secondary symptoms to the posterior fossa mass effect.[1,18] This may include obstructive hydrocephalus, with resulting headache, nausea and vomiting, and papilledema.[1,3,18] If hydrocephalus occurs before fusion of the cranial sutures (<18 months of age), then an increase in head circumference is likely.[5] We can encompass the clinical SNOOPY strategy developed by Franco and León in 2018[48] (Table 1), as a starting point in clinical evaluation.

Table 1. SNOOPY diagnostic strategy

S (Systemic)	Presence of systemic symptoms such as: pain, fever, weight loss, asthenia, vomiting (associated with oncological lesions).
N (Neurologic)	Neurological symptoms such as: paralysis, ataxia, aphasia, paresthesia.
O (Onset)	Of subacute clinical onset (depending on the temporality of neurological and systemic alterations).
O (Other)	Other associated causes such as: neurofibromatosis, tuberous sclerosis complex, tumor lesions or pre-existing hereditary diseases.
P (Progressive)	That the clinical manifestations are progressive (do not limit and increase the signs and symptoms).
Y (Image)	Presence of lesions by neuroimaging studies.

Timing strategy for the diagnosis of childhood brain tumors.

Neuroimaging

The diagnostic approach requires clinical suspicion necessarily combined with neuroimaging evaluation.[2,3] These studies are also essential because they provide information for preoperative planning, as well as the probable etiology, although finally the definitive diagnosis is given by the histopathological study.[1,10,47,49] At computed tomography (CT), most cerebellar and cerebral pilocytic astrocytomas have a well-demarcated appearance with a smaller round or oval shape.[10] At magnetic resonance (MR), pilocytic astrocytoma is typically isointense to hypointense relative to normal (Figure 1), brain with T1-weighted pulse sequences and hyperintense compared with normal brain with T2-weighted pulse sequences.[10] Reports of MR spectroscopy performed on the soft-tissue portions of pilocytic astrocytomas have documented elevation in the choline (Cho) to *N*-acetylaspartate (NAA) ratio, ranging from 1.80 to 3.40 (compared with 0.53–0.75 for normal cerebellum).[10]


Figure 1. Magnetic resonance imaging of the brain with cerebellar pilocytic astrocytoma.

Histological

PA are generally circumscribed slow growing cystic tumors.[2,3] Macroscopically, they often present with a solid mural soft gray nodule accompanied by a cyst.[35,50,51] PA are usually macroscopically discrete and displace rather than invade the surrounding brain, although parenchymal infiltration of several centimeters and invasion of the leptomeninges may be seen in cerebellar tumors.[35] Tumors of the visual pathway, including the optic nerve, often have less clear borders;[50-52] they can be followed to a point beyond which they become less cellular without a clear termination.[52] Chronic lesions can contain hemosiderin or calcifications.[35,52] Microscopically, PA consist of a variable proportion of compacted bipolar pyloid cells arranged in bundles associated with characteristic eosinophilic Rosenthal fibers interspersed with loosely textured stellate cells with microcysts and granular bodies.[35,53] Smear preparations show considerable cytological variation.[17,53] The term pilocytic refers to elongated hair-like projections that are similar to reactive astrocytes and show strong glial fibrillar acid protein (GFAP) staining .[35,53] The hair-like process can spread throughout the microscopic field.[53] Characteristically known as "protoplasmic astrocytes" they show a small b cell, eosinophilic granular bodies are globular aggregates within astrocytic processes and show periodic acid reactivity: Schiff, α1-antymotrypsin and α1-antitrypsin.[53] Oligodendroglioma-like cells can be seen in PA, especially at cerebellar sites.[17,35,53,54] The number of mitoses ranges from 0 to an exceptional 4 per 10 high-power fields, and the MIB-1 marking rates from 0 to 3.9%: these latter values overlap with those of grade II astrocytomas and they are not useful for the differential diagnosis between these entities. [54] PA are highly vascular.[35,53] Hyalinization of blood vessels is common.[35] Normal neurons can become entrapped and can cause confusion with gangliogliomas.[13,17,53] The distinction

between diffuse fibrillar astrocytoma and PA can sometimes be a matter of debate, although molecular findings may simplify the diagnosis.[35] A closely related tumor is pilomyxoid astrocytoma (classified as WHO grade II), which has an eminently mucoid matrix and an angiocentric arrangement of monomorphic bipolar tumor cells, without Rosenthal fibers or eosinophilic granular bodies/hyaline droplets and less frequently contains cystic components or large tumor cysts.[17,54] They are mainly located in the hypothalamic region and have a propensity for spreading cerebrospinal fluid and local recurrences.[17] Some PA may show considerable hyperchromasia and pleomorphism, with a diffuse growth pattern, infarct-like necrosis, glomeruloid vasculature, and infiltration of the leptomeninges that can mimic a high-grade diffuse astrocytoma.[35] PA recur mainly locally, especially when they are incompletely removed and/or located in unresectable sites.[55] They can also spread, mainly to the leptomeninges, and this can occur early in the history of the disease.[55] Pathology cannot predict such a propensity to spread.[54] Leptomeningeal deposits are usually slow growing and long-term survival is possible.[7]

TREATMENT

The treatment of PA depends largely on the host (patient) and the tumor itself, the variables that must be considered in the host are: age, pathological, prenatal and perinatal antecedents, inheritance or genetic load for lesions and nutritional status.[5,56] Regarding the variables to be considered for the tumor lesion they are: location, shape (by neuroimaging), degree of infiltration, and histology, also the prognosis and subsequent treatment are also dependent on the integrity of the extirpation.[56] Cerebellar astrocytoma is a surgical entity, and the primary treatment of cerebellar astrocytomas is surgical resection, with the goal of obtaining total tumor removal.[56] In fact, extent of resection is the main predictor of recurrence and survival.[5] Children are usually diagnosed when they already have symptoms as a consequence of increased intracranial pressure.[5] In those cases, in which there is cloudiness or cardiorespiratory instability, immediate intervention with the placement of an external ventricular drain is mandatory.[5] In these cases, the utmost care should be taken to avoid excessive drainage, which can result in an upward herniation.[5,55,56] Preoperative placement of an external ventricular drain in non-emergency cases is a matter of preference of the surgeon, but in the practice the surgeon prefers to avoid it and start with dexamethasone (0.25 to 0.5 mg / kg per day), which generally relieves symptoms in 6 to 12 hours.[2-5] The surgical approach will be the indication for medical management to address this injury.[1-3,5,55]The surgical approach will be determined by the location of the tumor, the general condition and the age of the patient.[5,53-57] The mainstay of treatment is surgical excision with the aim of completing the resection margins while achieving minimal neurological injury.[5,58] Complete resection is considered curative of the disease.[58] However, involvement of the brain stem or cranial nerves can prevent complete resection.[5] Resection of the nodule

only and not of the cyst wall is recommended.[58,59] However, tumors with a thick cyst wall can be considered part of the nodule and therefore excised.[58] Conventional radiation therapy is not required; instead, serial imaging is more appropriate.[60] Radiation therapy, particularly in this region of the brain, has significant sequelae.[60] If there is a recurrence, additional surgical resection is usually adopted.[60] Radiation therapy may be appropriate if it is surgically unresectable or if there is malignant histology.[61] In some studies, stereotactic radiosurgery (SRS) gave excellent results for residual and recurrent tumors.[50,61] Although, there has been criticism regarding the length of follow-up in these studies.[62] There is some concern that SRS may promote anaplastic transformation.[62]

The complete management for a correct diagnosis and subsequent treatment of astrocytomas, should contain a comprehensive protocol in which to evaluate: representative clinical data, neuroimaging studies, surgical approach and histological study of the tumor,[1,5] as shown in Figure 2.


Figure 2. Comprehensive diagnosis of astrocytomas.[1,5]

PREVENTION

There are no modifiable risk factors for PA.[58] Some genetic conditions such as NF1 predispose families to PA, and therefore genetic testing and counseling may be appropriate. However, most PA are due to sporadic mutations.[60-62] Epigenetic variations depend to a large extent on genetic inheritance and the environmental development to which they are exposed; however, in the case of pilocytic astrocytoma, the ideal is timely detection with immediate strategies and low cost of the first contact doctor[1,38] (Table 1).

PROGNOSIS

After complete resection, recurrence occurs in less than 5% of patients compared with up to 50% of those with residual disease.[56] The 10-year survival rate is nearly 100%.[57] Even after partial resections, patients can be observed and reoperation or other forms of treatment can be reserved for those with progressive disease.[35] Overall, the prognosis for patients with pilocytic astrocytoma is excellent, with a survival rate of 10 years of up to 94% and a 20-year survival rate of 79%.[10]

CONCLUSION

What is analyzed and documented in this article gives us a better overview of the importance of timely diagnosis, because by having assertiveness, the health of an infant can allow optimal neurodevelopment or a poor state with sequelae that decrease the quality of life of the child patient. Educating the first contact doctor allows the improvement of vulnerable populations.

REFERENCES

[1] Alegría-Loyola MA, Galnares-Olalde JA, Mercado M. Tumors of the central nervous system. Rev. Med. Inst. Mex. Seguro Soc. 2017;55(3):330–40.

[2] Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Fact sheet 2020. CBTRUS; 2020. https://cbtrus.org/cbtrus-fact-sheet-2020/

[3] Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro. Oncol. 2020;22–96.

[4] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424.

[5] Albright A, Pollack I, Adelson P. Principles and Practice of Pediatric Neurosurgery. In: Peruzzi P, Boué D, Courey R, editors. Cerebellar Astrocytomas. 3rd ed. New York: Thieme; 2013: 563-73.

[6] Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions: JNSPG 75th Anniversary Invited Review Article. J. Neurosurg. Pediatr. 2019;23:261–73.

[7] Pollack IF. Brain tumors in children. N. Engl. J. Med.1994; 331:1500–7.

[8] Kibirige MS, Birch JM, Campbell RHA, Gattamaneni HR, Blair V. A Review of Astrocytoma in Childhood. Ped. Hem. Oncol. 1989;6:319–29.

[9] Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J. Clin. Oncol. 2013; 31:2927–35.

[10] Koeller KK, Rushing EJ. From the archives of the AFIP: pilocytic astrocytoma: radiologic-pathologic correlation: Pilocytic astrocytoma: Radiologic-pathologic correlation. Radiographics. 2004;24:1693–708.

[11] Knight J, De Jesus O. Pilocytic Astrocytoma. In StatPearls Publishings. 2021; 30:14-24.

[12] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–20.

[13] Duffner PK, Krischer JP, Horowitz ME, Cohen ME, Burger PC, Friedman HS, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann. Neurol. 1998;44:313–6.

[14] Bauchet L, Ostrom QT. Epidemiology and molecular epidemiology. Neurosurg. Clin. N. Am. 2019;30:1–16.

[15] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: A summary. Neuro. Oncol. 2021;23:1231–51.

[16] Kruchko C, Ostrom QT, Gittleman H, Barnholtz-Sloan JS. The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. Neuro. Oncol. 2018;20(3):295–8.

[17] Louis DN, Ohgaki H, Od W. The 2007 WHO classification of tumours of the central nervous sys- tem. Acta Neuropathol. (Berl. 2007;114:97–109.

[18] Chico-Ponce-De-León F, Castro-Sierra E, Perezpeña-Diazconti M, Gordillo-Domínguez LF, Santana-Montero BL, Rocha-Rivero LE, et al. Tumores intracraneanos del niño. Bol. Med. Hosp. Infant. Mex. 2006;63:367–81.

[19] Matson D. Neurosurgery of infancy and childhood. 3rd ed. Springfield: Thomas; 1968: 934.

[20] Hoffmann HJ, Kestle JRW. Craniopharyngiomas. In: Cheek WR, editor. 3rd ed. Philadelphia: WB Saunders Company; 1994: 418–28.

[21] Ravi D, Vara Prasad K, Pallikonda V, Raman BS. Clinicopathological study of pediatric posterior fossa tumors. J. Pediatr. Neurosci. 2017;12:245.

[22] Kaye AH, Morokoff A. The continuing evolution: biology and treatment of brain tumors. Neurosurgery. 2014;61 Suppl 1:100–4.

[23] Packer RJ, Schut L, Sutton LN, Bruce DA. Brain tumors of the posterior cranial fossa in infants and children. In: En Y, editor. Philadelphia: WB Saunders Company; 1992. p. 3017–39.

[24] De la Torre Mondragón L, Ridaura Sanz C, Reyes Mujica M, Rueda Franco F. Central nervous system tumors in Mexican children. Childs Nerv. Syst. 1993;9:260–5.

[25] Bourgeois M, Sainte–Rose C, Lellouch–Tubiana A, Malluci C, Brunelle F, Maixner V, et al. Surgery of epilepsy associated with focal lesions in childhood. J. Neurosurg. 1999;90: 833–42.

[26] Paulas JE, Toga M, Hassoun J, Salamon G, Grisoli F. Les tumeurs cerebrales. Paris: Masson; 1982. p. 211.

[27] Cohadon F. Fisiopatologfa de los tumores intracraneales. In: Decq P, Kéravel Y, Velasco F, eds. Neurocirugía. México: JGH Eds; 1999. p. 77–83.

[28] González D, Loyo M. Tumores del sistema nervioso en el niño. Cir. Cir. 1972;40:55–78.

[29] Bruce DA, Schut L, Sutton LN. Supratentorial brain tumors in children. In: Youmans JR, editor. Neurological surgery. Philadelphia: WB Saunders Company; 1992. p. 3000–16.

[30] Humphreys RP. Posterior cranial fossa brain tumors in children. In: Youmans JR, editor. Neurological surgery. Philadelphia: WB Saunders Company; 1982: 2733–58.

[31] Tomita T. Miscellaneous posterior fossa tumors. In: CWR, editor. Philadelphia: WB Saunders Company; 1994: 383–91.

[32] Edwards MSB, Baumgartner JE. Pineal region tumors. In: CWR, editor. Philadelphia: WB Saunders Company; 1994: 429–36.

[33] Albright A, Pollack I, Adelson P. Principles and Practice of Pediatric Neurosurgery. In: Peruzzi P, Boué D, Courey R, editors. New York: Thieme; 1999: 491–514.

[34] Kristiansen I, Strinnholm M, Strömberg B, Frisk P. Clinical characteristics, long-term complications and health-related quality of life (HRQoL) in children and young adults treated for low-grade astrocytoma in the posterior fossa in childhood. J. Neurooncol. 2019;142:203–10.

[35] Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handb. Clin. Neurol. 2016; 134:329–44.

[36] Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68:8673–8677.

[37] Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 2008;118:1739–49.

[38] Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397–405.

[39] Collins VP, Jones DTW, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88.

[40] Collins KL, Pollack IF. Pediatric low-grade gliomas. Cancers (Basel). 2020;12:1152.

[41] Tjota MY, Pytel P. Educational case: Pilocytic astrocytoma with atypical features. Acad. Pathol. 2020;7:2374289520912498.

[42] Sithanandam G, Kolch W, Duh FM, Rapp UR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene. 1990;5:1775–80.

[43] Sithanandam G, Druck T, Cannizzaro LA, Leuzzi G, Huebner K, Rapp UR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene. 1992;7:795–9.

[44] Reis GF, Tihan T. Practical Molecular Pathologic Diagnosis of Pilocytic Astrocytomas. Surg. Pathol. Clin. 2015;8:63–71.

[45] Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH. Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. Transl. Oncol. 2012;5:430–6.

[46] Raabe EH, Lim KS, Kim JM. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 2011; 17:3590–9.

[47] Bergthold G, Bandopadhayay P, Bi WL, Ramkissoon L, Stiles C, Segal RA, et al. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim. Biophys. Acta. 2014;1845:294–307.

[48] Franco JJ, León F. Tiempo al diagnostico de los tumores cerebrales: Estrategia SNOOPY para el diagnostico de lesiones tumoraes. Bol. Med. Hosp. Infant. Mex. 2018;63:367–381.

[49] Anderson MD, Colen RR, Tremont-Lukats IW. Imaging mimics of primary malignant tumors of the central nervous system (CNS). Curr. Oncol. Rep. 2014;16:399.

[50] Jiang Y, Lv L, Yin S, Zhou P, Jiang S. Primary spinal pilocytic astrocytoma: clinical study with long-term follow-up in 16 patients and a literature review. Neurosurg. Rev. 2020;43:719–27.

[51] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.

[52] Goyal S, Puri T, Julka PK. Holocord low grade astrocytoma – Role of radical irradiation and chemotherapy. J. Egypt Natl. Canc. Inst. 2015;27:105–8.

[53] Onizuka H, Masui K, Komori T. Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System. Int. J. Clin. Oncol. 2020;25:997–1003.

[54] Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J. Neuropathol. Exp. Neurol. 1999;58:46–53.

[55] Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, et al. Low-grade astrocytoma with neuraxis dissemination at diagnosis. J. Neurosurg. 1995;83:67–71.

[56] Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery. 2012;70:40–7.

[57] Saunders DE, Phipps KP, Wade AM, Hayward RD. Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma. J. Neurosurg. Pediatr. 2005;102:172–8.

[58] Milde T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, Eberhart CG, Gutmann DH. Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro. Oncol. 2021;23:1634-46.

[59] Beni-Adani L, Gomori M, Spektor S, Constantini S. Cyst wall enhancement in pilocytic astrocytoma: neoplastic or reactive phenomena. Pediatr. Neurosurg. 2000;32:234–9.

[60] Austin EJ, Alvord EC Jr. Recurrences of cerebellar astrocytomas: a violation of Collins' law. J. Neurosurg. 1988;68:41–7.

[61] Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J. Clin. Oncol. 1993;11:850–6.

[62] Murphy ES, Parsai S, Kano H, Sheehan JP, Martinez-Alvarez R, Martinez-Moreno N, et al. Outcomes of stereotactic radiosurgery for pilocytic astrocytoma: an international multiinstitutional study. J. Neurosurg. 2019;1–9.